CN101422534A - Radio therapy sensitization composite preparation - Google Patents
Radio therapy sensitization composite preparation Download PDFInfo
- Publication number
- CN101422534A CN101422534A CNA2008101590157A CN200810159015A CN101422534A CN 101422534 A CN101422534 A CN 101422534A CN A2008101590157 A CNA2008101590157 A CN A2008101590157A CN 200810159015 A CN200810159015 A CN 200810159015A CN 101422534 A CN101422534 A CN 101422534A
- Authority
- CN
- China
- Prior art keywords
- cordycepin
- radio therapy
- composite preparation
- ganoderma spore
- therapy sensitization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a radiotherapy and enhancement combination preparation which is an oral liquid preparation prepared by cordycepin, wolfberry olysaccha prides, lingzhi spore and aloe extract. The combination preparation has no toxic side effect; all the components are processed and then combined, and promote each other in function. The combination preparation can be taken for strengthening the body resistance to consolidate the constitution of patients, fully protect normal cell from being damaged, actively adjust immunologic function, assist to kill tumor cells and enhance the radiotherapy effect.
Description
Technical field
The invention belongs to the radiotherapeutic sensitizer technical field, especially relate to a kind of Chinese medicine composition that can improve the tumour radiotherapy effect.
Background technology
Radiotherapy is one of main means of current treatment malignant tumor, 70% malignant tumor need radiotherapy is arranged clinically approximately, but because 20% ~ 50% oncocyte is in anoxia state in the solid tumor, its biological effect is poor, insensitive to lonizing radiation, it kills dosage is three times of aerobic cell required dosage, and these anoxic cells often become the growing point of local recurrence behind the oncotherapy.For this reason, from the 1950's, people begin one's study to explore and utilize sensitizer to improve radiotherapeutic effect, some achievements have also been obtained, find that nitro glyoxaline compound and nitro imidazole derivatives have the radiotherapy sensitization effect, but this class sensitizer fails to use clinically because toxic and side effects is big.A direction and a difficult problem that searching hypotoxicity, high curative effect sensitizer are this area researches always.At present, the Irisquinonum (" peace card ") that utilizes the Chinese medicine Semen Iridis to make begins to use clinically as tumour radiotherapy enhanced sensitivity medicine.Though this sensitizer has certain radiotherapy sensitization effect, still has certain toxicity, and it is little to the immunity of organism regulating action, and effect of enhanced sensitivity is undesirable.
Summary of the invention
The technical problem to be solved in the present invention provides and a kind ofly can effectively suppress tumor cell, has no side effect, and can protect normal cell to be without prejudice, and can be comprehensively, the active adjustment body's immunity, thereby improve the compound sensitizer of radiotherapeutic effect.
For solving the problems of the technologies described above, the present invention includes cordycepin, lycium barbarum polysaccharide and Ganoderma spore powder.
Also contain Aloe extract in the said composition.
Cordycepin is that Cordyceps militaris (L.) Link. extracts dry powder; Lycium barbarum polysaccharide is that Fructus Lycii is extracted dry powder, comprising arabinose, glucose, galactose, mannose, xylose, rhamnose; Ganoderma spore powder is a Ganoderma spore powder with cellular wall broken, and Aloe extract is an Aloe vulgaris blade extract dry product.
The weight proportion of each component is: cordycepin 2-5 part, lycium barbarum polysaccharide 3-10 part, Ganoderma spore powder with cellular wall broken 5-12 part, Aloe extract 3-7 part.
The preferred weight proportion of each component is: cordycepin 3-4 part, lycium barbarum polysaccharide 5-8 part, Ganoderma spore powder with cellular wall broken 7-10 part, Aloe extract 4-5 part.
Described preparation is oral formulations or soft capsule.
Cordycepin has another name called cordycepin (3 '-deoxyadenosine), be from Cordyceps militaris (L.) Link., to extract a kind of nucleoside antibiotics that obtains, it is a kind of cytotoxic substance and adenosine analog, can participate in the tumor cell metabolism, RNA interfering and DNA's is synthetic, suppress tumor cell and grow fast, have antiviral, antitumor action.Lycium barbarum polysaccharide be from Fructus Lycii, extract and a kind of water soluble polysaccharide, include arabinose, glucose, galactose, mannose, xylose, 6 kinds of monosaccharide compositions of rhamnose, has stronger biological activity, can control the division and the differentiation of cell, promote cellular immune function, strengthen the generation of lymphopoiesis and tumor necrosis factor.Ganoderma spore powder contains and enriches ganoderan class, ganoderma lucidum triterpene, nucleoside compound, phytosterin compound, has antitumor and immunoregulation effect.Contain anthraquinone analog compounds such as aloin, aloe-emodin, Aloin A, Aloe resin B in the aloe leaf, tumor cell is had remarkable killing activity, have antitumor action.
Because cordycepin, lycium barbarum polysaccharide, Ganoderma spore powder with cellular wall broken and Aloe extract all come from natural plants, itself has no side effect, and each component is through combination and compatibility, and effect is mutually promoted.The tumor radiotherapy patient uses, and can play strengthening the body resistance, and the general protection normal cell is without prejudice, and the effect of active adjustment body's immunity plays auxiliary kill activity again to tumor cell, strengthens radiotherapeutic effect.
The specific embodiment
Embodiment 1
Take by weighing cordycepin dry powder 2 grams, lycium barbarum polysaccharide dry powder 10 grams, Ganoderma spore powder with cellular wall broken 12 grams are ground into fine powder with cordycepin dry powder, lycium barbarum polysaccharide dry powder, behind Ganoderma spore powder with cellular wall broken and an amount of abundant mix homogeneously of sodium carboxymethylstarch, utilize tablet machine to make tablet or filled capsules gets final product.
Embodiment 2
Take by weighing cordycepin 3 grams, lycium barbarum polysaccharide 8 grams, Ganoderma spore powder with cellular wall broken 10 grams, Aloe extract 5 grams, cordycepin dry powder, lycium barbarum polysaccharide dry powder, Aloe extract are ground into fine powder, behind Ganoderma spore powder with cellular wall broken and an amount of abundant mix homogeneously of sodium carboxymethylstarch, are processed into tablet or capsule.
Embodiment 3
Take by weighing cordycepin 5 grams, lycium barbarum polysaccharide 3 grams, Ganoderma spore powder with cellular wall broken 5 grams, Aloe extract 3 grams are processed into tablet or capsule by embodiment 2 methods.
Embodiment 4
Get cordycepin 4 grams, lycium barbarum polysaccharide 5 grams, Ganoderma spore powder with cellular wall broken 7 grams, Aloe extract 4 grams are processed into tablet or capsule by embodiment 2 methods.
Cordycepin in this compound formulation is to utilize Cordyceps militaris (L.) Link. aspergillus nidulans (Aspergillus nidulans) culture fluid, perhaps Cordyceps militaris (L.) Link. (cordyceps militaris) sporophore, a kind of needle-like or the flaky crystal that adopt conventional process for separation and purification to obtain.Lycium barbarum polysaccharide is selected ripe dry wolfberry in Ningxia for use, makes the lycium barbarum polysaccharide coarse-grain with ethanol precipitation, and again through column chromatography, lyophilization obtains solid lycium barbarum polysaccharide elaboration, comprising arabinose, glucose, galactose, mannose, xylose, rhamnose.Ganoderma spore powder with cellular wall broken adopts red ganoderma sporophore spore, makes through the air-flow wall breaking pulverization.Aloe extract is with giving birth to Aloe vulgaris (AloebarbadensisMiller) blade more than 3 years, the yellow or the light yellow crystalline powder that utilize conventional extraction process to make mainly contain anthraquinones such as aloin, aloe-emodin, Aloin A, Aloe resin B.
The clinical practice example
Utilize embodiment 1 described composition capsule, do auxiliary treatment 20 routine advanced lung cancer patients, and compare with the 39 routine similar patients that other drug for increasing white cells are made auxiliary treatment, impose radiotherapy simultaneously, the completion rate of experimental group radiotherapy as a result 95%, hemogram natural rate of interest 85% is all apparently higher than matched group.
20 routine late malignant tumour patients are divided into 2 groups, wherein take embodiment 2 described composition capsules after 10 days for one group, 2 groups are carried out radiotherapy simultaneously, the not drug withdrawal of administration group radiation period, the back inspection of 2 week of radiotherapy, administration group patient focus reduction rate 100%, matched group focus reduction rate 80%, and administration group leukocyte count, liver function, kidney merit are significantly better than matched group.
Claims (7)
1, a kind of radio therapy sensitization composite preparation is characterized in that it comprises cordycepin, lycium barbarum polysaccharide and Ganoderma spore powder.
2, according to the described radio therapy sensitization composite preparation of claim 1, it is characterized in that also containing Aloe extract.
3,, it is characterized in that cordycepin is that Cordyceps militaris (L.) Link. extracts dry powder according to the described radio therapy sensitization composite preparation of claim 2; Lycium barbarum polysaccharide is that Fructus Lycii is extracted dry powder, comprising arabinose, glucose, galactose, mannose, xylose, rhamnose; Ganoderma spore powder is a Ganoderma spore powder with cellular wall broken, and Aloe extract is an Aloe vulgaris blade extract dry product.
4, according to the described radio therapy sensitization composite preparation of claim 3, it is characterized in that the weight proportion of each component is: cordycepin 2-5 part, lycium barbarum polysaccharide 3-10 part, Ganoderma spore powder with cellular wall broken 5-12 part, Aloe extract 3-7 part.
5, according to the described radio therapy sensitization composite preparation of claim 4, it is characterized in that the weight proportion of each component is: cordycepin 3-4 part, lycium barbarum polysaccharide 5-8 part, Ganoderma spore powder with cellular wall broken 7-10 part, Aloe extract 4-5 part.
6,, it is characterized in that described preparation is an oral formulations according to claim 4 or 5 described radio therapy sensitization composite preparations.
7,, it is characterized in that described oral formulations is a soft capsule according to the described radio therapy sensitization composite preparation of claim 6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101590157A CN101422534B (en) | 2008-11-18 | 2008-11-18 | Radio therapy sensitization composite preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101590157A CN101422534B (en) | 2008-11-18 | 2008-11-18 | Radio therapy sensitization composite preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101422534A true CN101422534A (en) | 2009-05-06 |
| CN101422534B CN101422534B (en) | 2011-11-30 |
Family
ID=40613565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101590157A Expired - Fee Related CN101422534B (en) | 2008-11-18 | 2008-11-18 | Radio therapy sensitization composite preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101422534B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614226A (en) * | 2012-04-24 | 2012-08-01 | 珠海市先康生物科技有限公司 | Application of cordyceps militaris link extract to preparation of health-care product or medicament for prompting leucocyte proliferation of breast cancer patient |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
| CN106822169A (en) * | 2017-01-22 | 2017-06-13 | 中国人民解放军第三军医大学 | Application of the cordycepin in the medicine for preparing prevention and/or radiotherapy damage and preparing tumor radiotherapy enhanced sensitivity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1084206C (en) * | 1999-05-20 | 2002-05-08 | 周金龙 | Cancer treating medicine and its preparation |
-
2008
- 2008-11-18 CN CN2008101590157A patent/CN101422534B/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614226A (en) * | 2012-04-24 | 2012-08-01 | 珠海市先康生物科技有限公司 | Application of cordyceps militaris link extract to preparation of health-care product or medicament for prompting leucocyte proliferation of breast cancer patient |
| CN105106959A (en) * | 2015-08-16 | 2015-12-02 | 深圳市倍昂生物科技有限公司 | Application of cordycepin in preparation of pharmaceuticals cooperating with radiotherapy and/or chemotherapy to treat tumors, and pharmaceutical composition |
| CN105106959B (en) * | 2015-08-16 | 2018-07-17 | 深圳市倍昂生物科技有限公司 | Application and a kind of pharmaceutical composition of the cordycepin in the drug of preparation and radiotherapy and/or chemotherapy synergistic treatment tumour |
| CN106822169A (en) * | 2017-01-22 | 2017-06-13 | 中国人民解放军第三军医大学 | Application of the cordycepin in the medicine for preparing prevention and/or radiotherapy damage and preparing tumor radiotherapy enhanced sensitivity |
| CN106822169B (en) * | 2017-01-22 | 2020-08-21 | 中国人民解放军第三军医大学 | Application of cordycepin in preparation of medicine for preventing and/or treating radiation injury |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101422534B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20050105435A (en) | Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits | |
| CN105031301A (en) | Anti-tumor traditional Chinese medicine composition and preparation method thereof | |
| CN101380346B (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN102008650A (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN101422534B (en) | Radio therapy sensitization composite preparation | |
| CN105796861A (en) | Application of forsythin, forsythin derivatives and composition of forsythin and forsythiaside to preparation of drug for improving immune function | |
| CN105287611A (en) | Application of ginsenoside Rh2 to inhibition of Treg cells | |
| CN105664140A (en) | Glycopeptide composition as well as preparation method and application thereof | |
| CN102133220B (en) | Preparation method of pulsatilla saponin A | |
| CN102389559B (en) | Traditional Chinese medicine composition and application as radiotherapy sensitizer | |
| CN106668041A (en) | Application of rhizoma paridis saponin VI to preparation of anti-lung cancer drugs | |
| CN108813610A (en) | A kind of saussurea involucrata composition and its application for improving immunity | |
| CN102641448B (en) | Anti-lung-cancer traditional Chinese medicine composite, preparation method of composite, and application of composite in preparation of anti-lung-cancer medicament | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN106176787A (en) | The application in preparing anticancer or antitumor drug of phillyrin, phillyrin derivant, phillyrin and phillygenol compositions and medicine | |
| CN100464759C (en) | Anticancer Chinese traditional extracts and preparation process and application thereof | |
| CN104189782A (en) | Anti-tumor medicament composition | |
| CN106038702B (en) | Antifatigue composition and its preparation method and application | |
| CN108853428A (en) | A kind of Chinese medicine preparation by improving immunity anticancer | |
| CN106109626B (en) | Pharmaceutical composition with anti-tumor effect and preparation method and application thereof | |
| EP3257517A1 (en) | The pharmaceutical composition for decreasing the side effects of cancer drug, and manufacturing method and uses thereof | |
| CN102423384B (en) | Traditional Chinese drug preparation for treating lung cancer, and preparation method thereof | |
| CN103191268B (en) | Traditional Chinese medicinal composition for treating lung cancer | |
| CN103585485B (en) | Anticancer medicine and preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111130 Termination date: 20121118 |